hyperparathyroidism

Genzyme sues former Bone Care employees

...Hectorol, a Vitamin D drug used to treat secondary hyperparathyroidism in patients on dialysis and in the early stages of chronic kidney disease. As part of a merger, Genzyme purchased BCI last July for an estimated $600 million. The former employees, Charles Bishop, Keith Crawford and Eric Messner, left Genzyme and st...

Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO

...development for vitamin D deficiency and secondary hyperparathyroidism in patients with moderate-to-severe CKD. Proventiv...ndary hyperparathyroidism. If untreated, secondary hyperparathyroidism can cause debilitating bone diseases and increased patient morbidity and mortality. At the moment, ...

Genzyme acquistion of Bone Care approved, significant impact forecast

... Pharmaceuticals - and is used to treat secondary hyperparathyroidism in patients on dialysis and early stages of chronic kidney disease. Hectorol will be added to Genzyme's renal line of products for treating chronic kidney diseases, joining the phosphorous-controlling drug Renagel. A combined sales force of Genzyme ...

FTC has fast-tracked Bone Care merger

...vel vitamin D hormone therapy, to treat secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition to chronic kidney disease, the company is developing vitamin D hormone therapies to treat hyperproliferative disorders such as cancer and psoriasi...

Bone Care expands patent protection of core drug offering

...covers the company's hormone therapy treatment for hyperparathyroidism in chronic kidney disease patients, as well as the new version of Hectorol which Bone Care is currently working to complete. Bone Care uses biotechnology developed at the UW to make drugs that treat the side effects of chronic kidney disease, such a...

Massachusetts firm to buy UW spinoff Bone Care for $600 million

... of renal disease drugs. Hectorol treats secondary hyperparathyroidism in patients with chronic kidney disease. While Genzyme's Renagel product has gained substantially in the market sales were up 19 percent in the first quarter compared to a year ago it is primarily used for late-stage patients already on dialysis. ...

FDA approves Bone Cares Hectorol for treatment of kidney disease

... currently approved for the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the United States, and is now approved for the treatment of SHPT that develops in the earlier stages (stages three and four) of chronic kidney disease (CKD). Current therapies for SHPT are primarily targeted for use in...

Americas Third Coast nurtures biotechnology

...The companys main drug, Hectorol, treats secondary hyperparathyroidism (SHPT) in patients with CKD. Healthy kidneys produce D hormone, which regulates calcium balance. Left untreated, low D hormone levels often trigger an imbalance causing parathyroid hormone levels to rise resulting in SHPT and, ultimately, the loss...

Bone Care Names New Chairman

...ved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney (renal) disease, osteoporo...ectorol(R) Capsules for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease....